摘要
目的探讨司美格鲁肽对肥胖2型糖尿病(T2DM)血糖、血清脂肪因子和内脏脂肪参数的影响。方法回顾性分析2022年6月至2024年1月在龙游县人民医院治疗的106例肥胖T2DM患者,采用倾向性匹配法按照1∶1分为联合组(二甲双胍组联合司美格鲁肽)和二甲双胍组(二甲双胍)各53例,均治疗2个月。比较2组治疗效果。结果治疗后,联合组总有效率94.3%高于二甲双胍组79.3%(P<0.05),联合组平均血糖波动幅度(MAGE)、内脂素、内脏脂肪指数(VAI)低于二甲双胍组,降脂素高于二甲双胍组[(3.37±0.51)mmol/L与(3.83±0.56)mmol/L,(65.35±6.28)μg/L与(71.58±6.88)μg/L,(80.06±7.71)μg/L与(85.19±8.12)μg/L,(5013.55±413.61)ng/ml与(4761.36±408.79)ng/ml,P<0.05];治疗后,2组不良反应差异无统计学意义(P>0.05)。结论司美格鲁肽可控制肥胖T2DM患者血糖波动,调节血清脂肪因子,改善内脏脂肪参数,安全有效。
Objective To explore the effects of semaglutide on blood glucose fluctuation,serum adipokines and visceral fat parameters in obesity patients with type 2 diabetes mellitus(T2DM).Methods A total of 106 obesity patients with T2DM treated in the hospital were retrospectively analyzed between June 2022 and January 2024.According to propensity matching method,they were divided into a combination group(metformin+semaglutide)and a metformin group(metformin),53 cases in each group.All patients were treated for 2 months.The curative effect in the two groups was compared.Results After treatment,total response rate of combination group was higher than that of metformin group(94.3%vs 79.3%,P<0.05).The mean amplitude of glycemic excur-sion(MAGE),visfatin and visceral adiposity index(VAI)in combination group were lower than those in metformin group,while adipsin was higher than that in metformin group[(3.37±0.51)mmol/L vs(3.83±0.56)mmol/L,(65.35±6.28)μg/L vs(71.58±6.88)μg/L,(80.06±7.71)μg/L vs(85.19±8.12)μg/L,(5013.55±413.61)ng/ml vs(4761.36±408.79)ng/ml,P<0.05].After treatment,there was no difference in adverse reactions between the two groups(P>0.05).Conclusion Semaglutide can control blood glucose fluctuation,regulate serum adipokines and improve visceral fat parameters in obesity patients with T2DM,which has high safety and effectiveness.
作者
程艺
雷永珍
Cheng Yi;Lei Yongzhen(Department of Pharmacy,Longyou County People′s Hospital,Quzhou,Zhejiang 324400,China;Department of Secrets,Longyou County People′s Hospital,Quzhou,Zhejiang 324400,China)
出处
《中国药物与临床》
CAS
2024年第15期959-963,共5页
Chinese Remedies & Clinics
基金
浙江省药学会医院药学专项科研资助项目(2023ZYY54)。
关键词
糖尿病
2型
司美格鲁肽
血糖
脂肪因子类
Diabetes mellitus,type 2
Semaglutide
Blood glucose
Adipokines
